Canaccord Genuity maintains Niagen Bioscience at Buy, lowers price target to $9 from $10

What happened

Canaccord Genuity kept its Buy rating on Niagen Bioscience but cut its price target to $9 from $10, a 10% reduction. The target was stated as implying 286.3% upside from the stock’s October 30 closing price of $2.33.

Confirmed

Global impact / market context

The lower target signals that Canaccord sees less potential value than before, even while retaining its Buy rating. If investors act on that view, their buying or selling could affect Niagen’s share price, but the article gives no evidence of an actual market reaction.

Analyst inference

The update is an analyst rating and price estimate, not a company announcement about sales, costs, or business plans. The stated upside compares a future analyst target with a past closing price, so it is not a forecast of guaranteed returns.

Analyst inference

What to watch

1. Watch for Canaccord’s next rating or target change; another cut or an upgrade would show whether its view of Niagen’s potential value is shifting. Analyst inference
2. Compare future company results with the assumptions behind the $9 target, if those assumptions are disclosed; the article does not provide them. Analyst inference
3. Track Niagen’s share price against the stated $2.33 October 30 close and $9 target, while recognizing that the target is an analyst estimate, not a promise. Analyst inference

Evidence

• Original source link unavailable